Not exact matches
DURECT Corp. is a biopharmaceutical company focused on two areas of active drug development:
New therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its epigenomic regulator progr
New therapeutics based on its proprietary drug delivery platforms and
new chemical entities derived from its epigenomic regulator progr
new chemical entities derived from its
epigenomic regulator program.
This study opens
new avenues of research aiming at integrating genomic and
epigenomic data together with environmental exposures in order to elucidate the physio - pathological mechanisms underlying asthma and to promote the development of
new therapies.
In a
new study published in the journal,
Epigenomics, the researchers focused on whether a post-weaning diet, or a diet later in life, could control the epigenome and affect metabolism in the body.
This exciting
new work has been published in the journal
Epigenomics.
The overall goal of the TGen study was to look at genomic and
epigenomic events to understand the causes of breast cancer brain metastatic lesions, and identify potential
new therapeutic targets.
IHEC aims to provide researchers with a comprehensive
epigenomic analysis of healthy and abnormal cells, and the
new studies constitute major strides toward that goal.
His lab develops novel single cell genomic and
epigenomic methods to characterize the immune system and develop
new targets for immunotherapy.